L
Lee M. Krug
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 184
Citations - 14788
Lee M. Krug is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung cancer & Mesothelioma. The author has an hindex of 57, co-authored 182 publications receiving 12736 citations. Previous affiliations of Lee M. Krug include Bristol-Myers Squibb & Cornell University.
Papers
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw,Kari Chansky,John Crowley,Ramón Rami-Porta,Hisao Asamura,Wilfried Ernst Erich Eberhardt,Andrew G. Nicholson,Patti A. Groome,Alan Mitchell,Vanessa Bolejack,David Ball,David G. Beer,Ricardo Beyruti,Frank C. Detterbeck,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Valerie W. Rusch,Nagahiro Saijo,Paul Van Schil,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone,F. Abad Cavaco,E. Ansótegui Barrera,J. Abal Arca,I. Parente Lamelas,A. Arnau Obrer,R. Guijarro Jorge,D. Ball,G.K. Bascom,A. I. Blanco Orozco,M. A. González Castro,M.G. Blum,D. Chimondeguy,V. Cvijanovic,S. Defranchi,B. de Olaiz Navarro,I. Escobar Campuzano,I. Macía Vidueira,E. Fernández Araujo,F. Andreo García,Kwun M. Fong,G. Francisco Corral,S. Cerezo González,J. Freixinet Gilart,L. García Arangüena,S. García Barajas,P. Girard,Tuncay Göksel,M. T. González Budiño,G. González Casaurrán,J. A. Gullón Blanco,J. Hernández Hernández,H. Hernández Rodríguez,J. Herrero Collantes,M. Iglesias Heras,J. M. Izquierdo Elena,Erik Jakobsen,S. Kostas,P. León Atance,A. Núñez Ares,M. Liao,M. Losanovscky,G. Lyons,R. Magaroles,L. De Esteban Júlvez,M. Mariñán Gorospe,Brian C. McCaughan,Catherine J. Kennedy,R. Melchor Íñiguez,L. Miravet Sorribes,S. Naranjo Gozalo,C. Álvarez de Arriba,M. Núñez Delgado,J. Padilla Alarcón,J. C. Peñalver Cuesta,Jongsun Park,H. Pass,M. J. Pavón Fernández,Mara Rosenberg,Enrico Ruffini,V. Rusch,J. Sánchez de Cos Escuín,A. Saura Vinuesa,M. Serra Mitjans,Trond Eirik Strand,Dragan Subotic,S.G. Swisher,Ricardo Mingarini Terra,Charles R. Thomas,Kurt G. Tournoy,P. Van Schil,M. Velasquez,Y.L. Wu,K. Yokoi +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
William Kevin Kelly,Owen A. O'Connor,Lee M. Krug,Judy H. Chiao,Mark L. Heaney,Tracy Curley,Barbara MacGregore-Cortelli,William P. Tong,J. Paul Secrist,Lawrence H. Schwartz,Stacy Richardson,Elaina Chu,Semra Olgac,Paul A. Marks,Howard I. Scher,Victoria M. Richon +15 more
TL;DR: Oral SAHA has linear pharmacokinetics and good bioavailability, inhibits histone deacetylase activity in PBMNCs, can be safely administered chronically, and has a broad range of antitumor activity.
Journal ArticleDOI
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
Vincent A. Miller,Mark G. Kris,Neelain Shah,Jyoti D. Patel,Christopher G. Azzoli,Jorge Gomez,Lee M. Krug,William Pao,Naiyer A. Rizvi,Barbara Pizzo,Leslie B. Tyson,Ennapadam Venkatraman,Leah Ben-Porat,Natalie Memoli,Manreen Zakowski,Valerie W. Rusch,Robert T. Heelan +16 more
TL;DR: The data suggest that individuals in whom gefitinib is efficacious are more likely to have adenocarcinomas of the bronchioloalveolar subtype and to be never smokers, and suggest that NSCLC has a different biology in patients who never smoked and those with bronchiola alveolar carcinoma.
Journal ArticleDOI
Non-small cell lung cancer: Clinical practice guidelines in oncology
David S. Ettinger,Wallace Akerley,Gerold Bepler,Matthew G. Blum,Andrew C. Chang,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Todd L. Demmy,Apar Kishor Ganti,Ramaswamy Govindan,Frederic W. Grannis,Thierry Jahan,Mohammad Jahanzeb,David H. Johnson,Anne Kessinger,Ritsuko Komaki,Feng Ming Kong,Mark G. Kris,Lee M. Krug,Quynh-Thu Le,Inga T. Lennes,Renato Martins,Janis P. O'Malley,Raymond U. Osarogiagbon,Gregory A. Otterson,Jyoti D. Patel,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Eric M. Rohren,George R. Simon,Scott J. Swanson,Douglas E. Wood,Stephen C. Yang +34 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease as discussed by the authors.
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
William D. Travis,Hisao Asamura,Alexander A. Bankier,Mary Beth Beasley,Frank C. Detterbeck,Douglas B. Flieder,Jin Mo Goo,Heber MacMahon,David P. Naidich,Andrew G. Nicholson,Charles A. Powell,Mathias Prokop,Ramón Rami-Porta,Valerie W. Rusch,Paul Van Schil,Yasushi Yatabe,Peter Goldstraw,David Ball,David G. Beer,Ricardo Beyruti,Vanessa Bolejack,Kari Chansky,John Crowley,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,Patti A. Groome,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Alan Mitchell,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Nagahiro Saijo,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone +78 more
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.